Evidence map›Paper›PMID 42238356›Full record

ArticleJournal of the American Statistical Association2024

Functional Integrative Bayesian Analysis of High-dimensional Multiplatform Clinicogenomic Data.

Rupam Bhattacharyya, Nicholas C Henderson, Veerabhadran Baladandayuthapani

Abstract read
In one paragraph

Article in Journal of the American Statistical Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rupam BhattacharyyaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48105.
Nicholas C HendersonDepartment of Biostatistics, University of Michigan, Ann Arbor, MI 48105.
Veerabhadran BaladandayuthapaniDepartment of Biostatistics, University of Michigan, Ann Arbor, MI 48105.

Funding

Graph-based Bayesian analysis of Genomics and Proteomics DataR01CA194391 · NCI · TEXAS A&M UNIVERSITY · PI BALADANDAYUTHAPANI, VEERABHADRAN, MALLICK, BANI K · 2016 to 2020
$2.0M
Bayesian Network-Based Integrative Genomics Methods for Precision MedicineR01CA244845 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BALADANDAYUTHAPANI, VEERABHADRAN, MORRIS, JEFFREY S · 2021 to 2024
$1.8M
Integrative methods for high-dimensional genomics dataR01CA160736 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BALADANDAYUTHAPANI, VEERABHADRAN · 2011 to 2014
$1.4M
Proteomic-based integrated subject-specific networks in cancerR21CA220299 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BALADANDAYUTHAPANI, VEERABHADRAN, HA, MIN JIN · 2018 to 2019
$378k
NCI NIH HHS R01 CA160736NCI NIH HHS R01 CA194391NCI NIH HHS R01 CA244845NCI NIH HHS R21 CA220299
6 · The paper itself

Abstract

Rapid advancements in collection and dissemination of multi-platform molecular and genomics data has resulted in enormous opportunities to aggregate such data in order to understand, prevent, and treat human diseases. While significant improvements have been made in multi-omic data integration methods to discover biological markers and mechanisms underlying both prognosis and treatment, the precise cellular functions governing these complex mechanisms still need detailed and data-driven de-novo evaluations. We propose a framework called Functional Integrative Bayesian Analysis of High-dimensional Multiplatform Genomic Data (fiBAG), that allows simultaneous identification of upstream functional evidence of proteogenomic biomarkers and the incorporation of such knowledge in Bayesian variable selection models to improve signal detection. fiBAG employs a conflation of Gaussian process models to quantify (possibly non-linear) functional evidence via Bayes factors, which are then mapped to a novel calibrated spike-and-slab prior, thus guiding selection and providing functional relevance to the associations with patient outcomes. Using simulations, we illustrate how integrative methods with functional calibration have higher power to detect disease related markers than non-integrative approaches. We demonstrate the profitability of fiBAG via a pan-cancer analysis of 14 cancer types to identify and assess the cellular mechanisms of proteogenomic markers associated with cancer stemness and patient survival.

Indexed as

Bayesian variable selectionCancer clinicogenomicsGaussian processesmulti-omic data integrationproteogenomic analyses

Identifiers

PMID42238356
PMCPMC13229388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.